|
|
Volumn 26, Issue 8, 2008, Pages 844-845
|
|
Infections cast cloud over Novartis' MS therapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
BAF 312;
BELIMUMAB;
CD52 ANTIGEN;
CLADRIBINE;
DACLIZUMAB;
FINGOLIMOD;
FUMARIC ACID DIMETHYL ESTER;
GLATIRAMER;
LAQUINIMOD;
LT 1009;
MONOCLONAL ANTIBODY;
NATALIZUMAB;
OCRELIZUMAB;
R 3477;
SONEPCIZUMAB;
SPHINGOSINE 1 PHOSPHATE;
SPHINGOSINE 1 PHOSPHATE RECEPTOR;
TERIFLUNOMIDE;
THERMOZYMOCIDIN;
UNCLASSIFIED DRUG;
ANTIANGIOGENIC ACTIVITY;
CELL MOTION;
CLINICAL TRIAL;
DRUG BINDING;
DRUG INDUSTRY;
DRUG MECHANISM;
HERPES SIMPLEX ENCEPHALITIS;
HUMAN;
IDIOPATHIC THROMBOCYTOPENIC PURPURA;
INFECTION;
LYMPH NODE;
LYMPHATIC LEUKEMIA;
MEMORY T LYMPHOCYTE;
MULTIPLE SCLEROSIS;
NOTE;
PRIORITY JOURNAL;
RELAPSE;
SKIN CANCER;
THYMUS;
VARICELLA ZOSTER VIRUS;
DRUG INDUSTRY;
HUMANS;
MULTIPLE SCLEROSIS;
PROPYLENE GLYCOLS;
SPHINGOSINE;
VIRUS DISEASES;
|
|
EID: 49449116795
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0808-844 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
